COVID drug patents: NIH MPP and WHO reached licensing agreement to allow pharmaceutical companies in various countries to use
- FDA: Investigation into Multistate Salmonella Outbreak Linked to Jif Peanut Butter
- ABBV-951: AbbVie submits new drug application for Parkinson’s disease
- Alert: Monkeypox belongs to the same genus of Orthopoxvirus as smallpox
- New study finds new coronavirus long-term hiding in intestine and feces
- New breakthrough: This collagen can make tumor cells go dormant!
- Lilly’s blockbuster new hair loss drug is expected to be launched this year
COVID drug patents: NIH MPP and WHO reached licensing agreement to allow pharmaceutical companies in various countries to use.
- Unexplained acute hepatitis in children may be related to COVID superantigens
- How long can the patient live after heart stent surgery?
- Keytruda: The 5-year survival rate for advanced lung cancer doubled!
- Amylyx released the latest statistical analysis of new ALS drugs after being opposed by FDA panel last month
- Celine Dion is paralyzed due to muscle cramps: What are Muscle Cramps?
- Taiwan death from COVID-19 vaccination exceeds death from COVID-19
- The world top 5 best-selling drugs in 2020
COVID drug patents: NIH MPP and WHO reached licensing agreement to allow pharmaceutical companies in various countries to use.
On May 12, the World Health Organization (WHO) announced that its COVID-19 Technology Access Pool (C-TAP) and Medicines Patent Pool (MPP) have reached a licensing agreement with the National Institutes of Health (NIH).
NIH awarded 11 COVID-19 patented technologies to the former in order to make them accessible to more companies and develop more commercial products that meet current and future public health needs.
These licenses are transparent, global and non-exclusive and allow pharmaceutical companies around the world to partner with MPP, C-TAP, and make these technologies accessible to people in low- and middle-income countries to help end the COVID-19 pandemic.
In most cases, the NIH does not collect royalties on licensed products from the 49 countries classified as least developed by the United Nations.
The 11 COVID-19 patented technologies in the agreement include the prefusion spike protein used in vaccine development, as well as other development, research, and diagnostic tools.
WHO COVID-19 Technology Access Pool
In May 2020, WHO and partners launched the COVID-19 Technology Access Pool (C-TAP) to facilitate timely, equitable and affordable access of COVID-19 health products by boosting their supply. C-TAP provides a global one-stop shop for developers of COVID-19 therapeutics, diagnostics, vaccines and other health products to share their intellectual property, knowledge, and data, with quality-assured manufacturers through public health-driven voluntary, non-exclusive and transparent licenses.
By sharing intellectual property and know-how through the pooling and these voluntary agreements, developers of COVID-19 health products can facilitate scale up production through multiple manufacturers that currently have untapped capacity to scale up production.
………
COVID drug patents: NIH MPP and WHO reached licensing agreement
(source:internet, reference only)
Disclaimer of medicaltrend.org
